

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 August 2006 (10.08.2006)

PCT

(10) International Publication Number
WO 2006/083271 A2

(51) International Patent Classification:

C07C 335/26 (2006.01) A61P 31/12 (2006.01)
A61K 31/17 (2006.01) C07D 211/22 (2006.01)

Connecticut 06410 (US). **OHKANDA, Junko** [JP/JP];
2-13-29 Gakuennishi-machikodaira, Tokyo, 187-0045
(JP).

(21) International Application Number:

PCT/US2005/017308

(74) Agent: **HORVATH, Leslie-anne**; CANTOR COLBURN
LLP, 55 Griffin Road South, Bloomfield, Connecticut
06002 (US).

(22) International Filing Date: 17 May 2005 (17.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/572,156 18 May 2004 (18.05.2004) US

(71) Applicant (for all designated States except US):
ACHILLION PHARMACEUTICALS, INC. [US/US];
300 George Street, New Haven, Connecticut 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PHADKE, Avinash**
[IN/US]; 51 Gilbert Lane, Branford, Connecticut 06405
(US). **CHEN, Dawei** [CN/US]; 4132 Town Place, Mid-
dletown, Connecticut 06457 (US). **DESHPANDE, Milind**
[US/US]; 44 Field Brook Rd., Madison, Connecticut
06443 (US). **THURKAUF, Andrew** [US/US]; 163 Keeler
Drive, Ridgefield, Connecticut 06877 (US). **WANG,**
Xiangzhu [CN/US]; 4 BRUSHY PLAIN ROAD, Apt.
#224, Branford, Connecticut 06405 (US). **SHEN, Yiping**
[CN/US]; 92 Village Lane, Branford, Connecticut 06405
(US). **LIU, Cuixian** [CN/US]; 4 Stoneridge Lane, Bran-
ford, Connecticut 06405 (US). **QUINN, Jesse** [US/US];
55 Allen Rd., Windsor, Connecticut 06095 (US). **LI,**
Shouming [CN/US]; 6 Brookfield Court, Cheshire,

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION



(57) Abstract: The invention provides compounds and pharma-
ceutically acceptable salts of Formula (I) wherein the variables A₁,
A₂, R₁, R₂, V, W, X, Y, and Z are defined herein. Certain com-
pounds of Formula (I) described herein which possess potent anti-
viral activity. The invention particularly provides compounds of
Formula (I) that are potent and/or selective inhibitors of Hepatitis
C virus replication. The invention also provides pharmaceutical
compositions containing one or more compound of Formula (I),
or a salt, solvate, or acylated prodrug of such compounds, and one

or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients
suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to re-
duce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections.
The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses
methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.
Methods of treatment include administering a compound of Formula (I) as a single active agent or administering a compound of
Formula (I) in combination with one or more other therapeutic agent.